Sophie is Managing Partner at Partners4Access, the global access experts for orphan drugs, cell and gene therapy. She brings a wealth of commercial and access experience across orphan and cell and gene therapies to the benefit of clients. She plays an active role in advising clients on price and market access strategies, with the ultimate goal of optimizing fair access for all stakeholders in rare disease. Her 20+ year career spans various disease areas and medical devices, successfully supporting the strategy development and operationalisation for orphan drugs. Her extensive industry experience across several product launches ensures clients benefit from that knowledge and build stronger access strategies as a result. Managing global, regional and local teams has provided her with the know-how to successfully face the real-life challenges in today’s orphan, cell and gene therapy world.
Stuart has worked in global and European pricing and market access for over 20 years.
Following the acquisition of PriceSpective by ICON in 2012, he was the European Head and Global Head of the Pricing and Market Access consulting team. He has led consulting projects for several large, medium and small biopharma companies, across a wide range of therapy areas and all phases of development, with a focus on in-licensing evaluations, Phase III planning, launch pricing and market access and loss of exclusivity planning. In addition, he has led projects advising clients on internal process and infrastructure.
During his industry tenure, he has worked at GSK where responsibilities included pricing and reimbursement strategy for pipeline products, price management of marketed products and managing the in-house price database. Stuart has a degree in mathematics from Oxford University and a masters in Operational Research.
Akshay is a Partner at Partners4Access. Akshay has 13+ years of experience helping pharmaceutical and biotech companies develop market access & pricing solutions – which are aligned to their broader commercial, organisational and environmental context. These solutions could be at the product, process and/or capability level. Besides market access, Akshay also has supported pharmaceutical companies in allied commercial areas such as – epidemiology, opportunity assessments, product positioning, product performance tracking, customer insights, and organisational design.
Prior to joining Partners4Access, Akshay worked at Huron Consulting as Senior Director – Orphan Drugs, Cell & Gene Therapy commercialisation and at ZS Associates initially as European Market Access and Pricing Lead and then as Global Epidemiology Practice Lead. He holds a D.Phil (PhD) in Materials from University of Oxford.
Aparna has over 10 years’ experience in the pharmaceutical and healthcare industry. Her primary focus is on strategic corporate engagement, public affairs, operations and brand awareness. She has previously worked as Manager, Life Sciences at IHS Markit and as Consultant at Parexel’s Commercialization unit among others specializing in market access, pricing and reimbursement. Aparna has a Bachelors’ degree in Life Sciences and a Masters in International Finance, with a focus on econometric modelling on the pharmaceutical industry.
Nicola is a registered pharmacist with 8 years of research and consulting experience. Prior to joining Partners4Access, she worked at ICON Plc and Precision for Value on various pricing and market access strategies for pharmaceutical and biotechnology companies.
She was an invited plenary presenter at ISPOR Europe on the future of health technology assessment (HTA) in Europe and is lead author of several papers on HTA published in peer reviewed journals, including Value in Health, Frontiers in Pharmacology, Journal of Health Policy and the Canadian Medical Association Journal Open.
Nicola received her Ph.D. from Cardiff University whilst working as Research Fellow for The Centre for Innovation in Regulatory Science, formerly part of Thomson Reuters, where she developed a novel reimbursement mapping methodology that is now a commercial product. Nicola has a Masters of Pharmacy from Cardiff University and completed her pre-registration pharmacy training at the Oxford University Hospitals NHS Foundation Trust.
Joanna’s main responsibilities at P4A include developing current and future landscape assessments, market research, and funding analysis, including innovative payment methods. Her key focus is on Cell and Gene therapy but has worked on a number of projects across a range of therapy areas, including immune-oncology, rare and ultra-rare diseases. She has completed a B.Sc. in Biochemistry at Imperial College London, focusing on infectious diseases and biotechnology. Prior to Partners4Access, she worked as an analyst at Finalta, Mckinsey Solutions, allowing her to further develop her primary and secondary research skills.
Max works on a range of projects including primary and secondary research, writing and testing value propositions and preparing landscape assessments to support the development of market access strategies for clients in the biotechnology and pharmaceutical industries. He has a keen interest in Cell and Gene therapy. Prior to joining P4A, he worked as an analyst at McKinsey, having previously completed a Research Master’s in Molecular and Cellular Biosciences and a BSc in Biochemistry at Imperial College London. He carried out research on a variety of topics, including identifying novel targets for a malaria vaccine and researching the mechanisms by which pathogens evade the immune response in humans.
Jack’s work at P4A involves conducting primary and secondary research for landscape and pipeline assessments to support the development of market access and reimbursement strategies. He has a passion for Cell and Gene therapy and has provided analysis on projects in these areas, as well as writing blog articles on the subject.
Before joining P4A he completed an M.Sc. in Drug Discovery and Development at University College London, focussing on personalised anticancer medicine, pharmacogenomics, and biomarkers. He was part of a research project at the Rayne Institute utilising gene ontology in cancer. Prior to this, he worked in the drug discovery lab at Westminster University, and at the Chinese University of Hong Kong. He has a B.Sc. in Biology and Management from Imperial College London.
Ciaran has a passion for innovative therapies and orphan diseases. He has experience in designing value communication for a novel biomedical technology, interviewing KOLs, and conducting secondary research into precision medicine for areas of unmet need in cancer.
Prior to P4A, he worked in Quality Assurance for an international pharmaceutical company and then in Business Development for a biotech start-up pioneering novel genetic diagnostics. He has a B.Sc.in Pharmacology from King’s College London and an M.Sc. in Drug Discovery and Pharma Management from UCL.
Erfan’s role at Partners4Access includes conducting primary and secondary research to support the development of market access and reimbursement strategies. He has a passion for innovations within neuroscience and the cell and gene-therapy space.
Erfan holds a B.Sc. in Biomedical Science from the University of Southampton and a M.Sc. in Neuroscience from King’s College London where he conducted a full-time research project within the KCL Neuroscience laboratory.
Veda’s role at Partners4Access includes analysing primary and secondary research, writing and testing value messages and examining differences in pricing to support the development of market access and reimbursement strategies. Veda has a passion towards innovations within immunology and the cell and gene-therapy field.
Prior to joining Partners4Access, Veda holds a M.Res in Translational Medicine from Imperial College London and conducted a full-time research project at the prestigious Imperial Clinical Research Facility. She was further awarded a dual qualification with a B.Sc. in Biomedical Science and PgDip. Immunology from King’s College London where she undertook a full-time research project at the Centre for Inflammation Biology and Cancer Immunology.
As an associate of P4A, Julie provides an in-depth understanding of the complex matrix that determines optimal market access in the U.K. She has spent the last 20 years working in the pharmaceutical industry as part of numerous commercialisation and launch execution teams and latterly as a consultant supporting clients to achieve the optimal access for their assets. Julie is passionate about bringing the strategy to life through excellence in HTA planning and implementation, value communications and payer-stakeholder engagement.
Anthony focuses on improving commercial effectiveness via insights and actions implemented at the executive level. The chief, but not only, focus in improving commercial effectiveness is by gaining and maintaining US and global market access. Anthony has held industry leadership positions in the East Coast, California, and in Europe at, respectively, Synageva, ALZA and Amgen. In addition to over 10 years of experience in industry and several years in consulting, he spent a decade at RAND. Anthony has a doctorate in Economics from the Stanford Graduate School of Business.
Justin supports pharma and biotech clients with Market Access strategy and execution. This includes strategy development, payer insight & engagement and project management support to produce local market access deliverables. He has worked in various Market Access and Commercial Director roles at GlaxoSmithKline with international responsibilities for Market Access and pricing strategies, evidence generation to meet payer requirements, product launches and commercial strategy for pipeline assets.
Joel has over 40 years of experience in U.S. managed care pharmacy. He was most recently Vice President, Health Policy-Strategy for Alliance Life Sciences Consulting Group (ALSCG), a global innovative management and technology consultancy, and formerly Vice President, Chief Pharmacy Officer, for Excellus Health Plans, NY.
As one of the early innovators in the development of clinical pharmacy programs within managed care, he has pioneered numerous clinical management and specialty programs, including Drug Information (1977), Pharmacokinetic evaluation program (1978), Anticoagulation Services (1979), Home Intravenous Therapy Service (1982), and Terminal Care/hospice programs (1984) among others. He has worked with a number of pharmaceutical companies, assessing US pharmaceutical market access potential for Phase I-III drugs, including specialty products, orphan drugs, and biosimilars. He has participated in and managed multiple advisory boards and has developed databases and applications profiling and tracking the new Health Care Exchange payer, benefits, and formulary information.
Steve’s pharmaceutical career has been built on a keen understanding of US Managed Markets. Over the last 27 years Steve has built strong relationships with US Payers across channels including commercial, government and hospital. His main areas of expertise are managed care strategy and launches, global pricing and market access, contracting, innovative contracting and partnership, traditional and specialty distribution, payer lead for multiple launches including joint venture management and development and management of pricing committees BD. Steve currently heads MKO Group in the US.